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INTRODUCTION
C1qTNF related protein-1 (CTRP-1) belongs to a family of proteins characterized by a common TNF alpha-like globular domain [1] [2] [3] . A second, less conserved structural element in this family is the N-terminal collagen-like region with typical Glycine-X-Y repeats. The basic structure of proteins in the CTRP family appears to be a trimer that in turn can form higher order structures 4 . While structurally related, members of this protein family are functionally diverse and include the plasma protein C1q that is involved in immune functions and possibly platelet hemostasis 5 , Adiponectin [6] [7] [8] and the hibernation proteins 20, 25, 27, which are thought to be regulators of metabolism 9 . Other CTRP family members appear to have more structural or extracellular matrix-related functions, e.g. collagen types VIII and X, and CTRP-5 10 .
Since C1q may play a role in collagen-induced platelet activation 11 , we investigated whether CTRP-1 might exhibit similar properties. Initial studies indicated that CTRP-1 had affinity for collagen and blocked collagen-induced platelet activation. This raises the potential significance of CTRP-1 for human disease because of the central role collagen-induced platelet activation and thrombus formation plays in acute cardio-and cerebrovascular events.
Spontaneous rupture of atherosclerotic plaque or medical interventions can cause an injury to the arterial endothelial lining thus exposing the subendothelial extracellular matrix to circulating blood. Collagens are a major component of the extracellular matrix and can directly and indirectly activate platelets [12] [13] [14] [15] [16] . Three platelet receptors are thought to mediate these interactions. Integrin α2β1 is thought to have a major role in adhesion and platelet anchoring; GPVI, a member of the Ig superfamily is responsible for collagen binding, signalling and platelet activation, and GPIb-V-IX (GPIb), through its indirect binding to collagen-bound 'von Willebrand's factor' (vWF), enables the initial 'rolling' of platelets on a collagen-containing surface under high shear conditions [12] [13] [14] [15] [16] [17] [18] .
In the present work, the mechanism by which CTRP-1 interferes with activation and aggregation of platelets by collagen was investigated and the efficacy to prevent platelet thrombosis in vivo was tested.
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MATERIALS AND METHODS

All procedures involving animals were approved by the Institutional Animal Care and Use
Committee (University of Washington Regional Primate Center).
Protein expression, purification and characterization. Full-length recombinant human CTRP-1 was produced in CHO-DG44 cells transformed with a pZMP18-CTRP-1 expression vector. CTRP-1 was purified to homogeneity from the cell culture medium by sequential chromatographic steps and was characterized by various methods including amino acid analysis, N-terminal sequencing and peptide mapping. CTRP-1 was dissolved in PBS and stored at -80°C.
Expression and purification of soluble GPVI-Fc4 fusion proteins. Expression constructs
encoding two versions of soluble human GPVI-Ig fusion proteins were generated by overlap PCR 19 and homologous recombination in yeast 20 . The first construct encoding GPVI-wtγ1Fc was modeled after the version described 18 . The second version encoding GPVI-Fc4 contained the same mouse κ signal sequence and GPVI extracellular domain sequences, but included a modified human IgG 1 Fc containing amino acid substitutions which prevent FcγRI binding and complement fixation 21 . were labeled to specific activities of 4300 and 4900 cpm/ng, respectively. More than 95% of the cpm in the final preparations were precipitated in 10% TCA.
Preparation of
Synthesis and cross-linking of collagen-related peptide (CRP). CRP was synthesized
(GKPGPPGPPGPPGPPGPPGPPGPPGPPGPPGPPGKPGV) and cross-linked with glutaraldehyde as described 22 . Valine was added to the sequence to improve recovery during resin cleavage, a molar ratio of CRP:glutaraldehyde of 1:290 was used. The majority of the cross-linked product was 30 kDa or larger.
Preparation of collagen, BSA, or CRP coated plates. MaxiSorp microtiter plates (Nunc #473768) were coated overnight at 37°C with equine fibrillar collagen I (Chrono-Par #385, Collagen-induced platelet aggregation. Collagen-induced platelet aggregation was performed using human platelet-rich-plasma (PRP). CTRP-1 was mixed with PRP by gentle rocking in a 96-well flat bottom plate. Collagen-I was added at a final concentration of 1.25 µg/mL and the plate was agitated at 37ºC on the microplate reader, turbidity was monitored as percent light transmitted at 632 nm after 21.5 min as described previously 23 . Platelet aggregation was determined in an aggregometer and platelet activation by measuring ATP release using a Chrono-Lum® luciferase reagent (Chrono-Log Col) following the manufacturer's instructions.
Platelet Aggregation Under Flow Conditions. The parallel plate flow chamber 24 was composed of a polycarbonate slab, a silicon gasket, and a glass coverslip coated with type I collagen (Helena Labs, Beaumont, TX). Coverslips were incubated with a solution of 100 µg collagen or vWF/mL for 1 h at 37°C. Citrated whole blood alone or with 20 µg CTRP-1/mL added was incubated for 5 min at room temperature, the platelets were labeled by incubating the blood sample with 0.2M mepacrine for 10 min in the dark, and the blood was perfused over the slide containing the immobilized collagen. A syringe pump was connected to the outlet port that drew blood through the chamber at defined flow rates (13 and 50 dynes/cm 2 )
to generate a wall shear. The flow chamber was mounted onto an inverted stage microscope equipped with a high speed digital camera. Images were analyzed offline using MetaMorph Imaging System. These data demonstrate that binding of 125 I-CTRP-1 to fibrillar collagen type I was saturable, specific, reversible and of relatively high affinity. Fig.4A) . Addition of 25 µg/mL CTRP-1, the highest concentration tested, reduced vWF binding to background levels. Under these conditions, CTRP-1 appeared to be more potent at blocking vWF binding to type I versus type III collagen.
Two separate domains of vWF, the A1 and A3 domains appear to mediate collagen binding 17 and their role was tested using purified A1 and A3. In the absence of added A1 domain, and in the absence or presence of 10 µg/mL CTRP-1, little or no A1 was detected on the collagen coated plates. Addition of A1 led to A1 binding to collagen I and III that was reduced in a dose-dependent manner by CTRP-1 (Fig. 4B) . The binding of A1 domain to collagen type I was reduced to a greater extent by CTRP-1 than the binding to collagen type III. A1 binding to collagen type I was reduced to background levels by 25 µg/mL CTRP-1 (Fig.4B) , similar results were observed for A3 domain binding (Fig. 4C) .
CTRP-1 does not prevent platelet "rolling" on a vWF-coated surface under high shear.
Platelet adhesion to collagen under high shear requires the interaction of the platelet GPIb receptor with vWF bound to collagen through its A3 domain. The A1 domain of vWF, though able to bind collagen on its own and thought to also mediate the platelet-vWF interaction has a fast on/off rate producing the well-described "rolling" of platelets on a vWF-coated surface under high shear. To assess whether CTRP-1 could block the GPIbvWF interaction, citrated whole blood was incubated for 5 min at room temperature with either vehicle alone or with vehicle containing 20 µg/mL CTRP-1 and flowed over a vWF coated surface at 50 dynes/cm 2 . Platelet rolling over the vWF-coated surface was observed in the presence (Fig. 3 lower right panel) or absence (Fig. 3 lower left panel) of CTRP-1.
Thus, CTRP-1 did not significantly affect the interaction of GPIb with vWF. Synthetic 'collagen-related peptide' (CRP), cross-linked with glutaraldehyde was used as functional agonist for GPVI 16, 26 . In preliminary studies, cross-linked CRP (CRPxl) was a potent inducer of platelet aggregation (EC 50 0.26 ±0.07 µg/mL), which could be blocked by GPVI-Fc4. Saturation analysis revealed that binding of 125 I-GPVI-Fc4 to CRPxl was saturable at 10-30 µg/mL, specific, and of high affinity (data not shown). Little or no specific binding of 125 I-GPVI-Fc4 to an unrelated control peptide was observed. Scatchard plots of the specific binding data were curvilinear, indicating two classes of sites. The K d
Effect
and B max for the high affinity site were 0.076 ± 0.016 µg/mL and 2.45 ± 0.19 ng bound/well and 2.43 ± 0.58 µg/mL and 15.4 ± 4.0 ng bound/well for the low affinity site. Binding of 125 I-GPVI-Fc4 to CRPxl was reduced by unlabeled GPVI-Fc4 in a dose-dependent manner (Fig. 6) . Unlabeled CTRP-1 also reduced the amount of 125 I-GPVI-Fc4 bound, but compared with GPVI-Fc4 it was a less effective competitor (Fig.6 ). These data demonstrate that both CTRP-1 and GPVI-Fc4 recognize and bind to CRPxl. The relative affinity of GPVI-Fc4 binding to CRPxl is however more than 20-times higher than that observed for CTRP-1.
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Effect of CTRP-1 on the binding of collagen to α2β1 integrin under static conditions.
Platelets also interact with collagen through the α2β1-platelet receptor, an interaction mediated by the I-domain of α2β1 16, 22 . To evaluate, whether CTRP-1 can inhibit the α2β1 integrin pathway, the ability of CTRP-1 to compete for I-domain binding to collagen was examined. In the absence of added I-domain, and in the presence or absence of 10 µg/mL CTRP-1, little or no I-domain was detected on plates coated with either collagen I or III.
Exogenous I-domain bound to both types of collagen as detected by the anti-I domain specific antibodies. In contrast to the inhibition of intact vWF or vWF A1 and A3 domain binding to collagen, under identical conditions, CTRP-1 failed to compete for I-domain binding (Supplement Fig. 2 ). These data suggest that the collagen binding domains of α2β1
integrin and CTRP-1 are distinct. 25 . A mechanical crush injury was made to the carotid artery of non-human primates (Macaca fascicularis) and blood flow through the injured, highly thrombogenic blood vessel was Using the purified I-domain 16 of the α2β1 receptor, we observed that CTRP-1 had no measurable effects on I-domain binding to collagen, suggesting inhibition of collagenmediated platelet functions by CTRP-1 is independent of the α2β1 platelet receptor.
In vivo anti-thrombotic effects of CTRP-1 in a Folts vascular injury model
Taken together, these data suggest a dual mechanism for the inhibition of collagen-induced platelet function by CTRP-1; a major mode of action appears to be the blockade of vWF binding sites on collagen leading to the prevention of platelet interaction with collagen in particular under arterial, high-shear blood flow conditions. Blockade of GPVI binding sites on collagen might represent a secondary and additive mechanism for the action of CTRP-1.
However, this does not sufficiently explain the mechanism by which CTRP-1 can prevent platelet aggregation under static conditions in vitro. Although unlikely, it is possible that CTRP-1 interacts directly with vWF, CRP and GPVI to prevent their interaction with collagen. Certainly, the partial blockade of the GPVI binding site on collagen could account for some of the effects of CTRP-1 under these conditions. In addition, a recent report by Bernado et.al. 36 demonstrates that fibrillar collagen as used in the current studies is show that CTRP-1 can act as a potent anti-thrombotic, preventing platelet thrombosis on an otherwise highly thrombogenic injured carotid artery. Interestingly, two measures of hemostasis indicated normal hemostasis in the treated animals. Adverse bleeding, seen when using current anti-thrombotic agents represents a small, but real clinical problem and the search for a 'magic bullet', i.e. anti-thrombotic therapy with no or only negligent effect on general hemostasis is a topic of ongoing investigations 37, 38 .
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FIGURE LEGENDS FIGURE 1 CTRP-1 prevents collagen induced platelet activation and aggregation.
Collagen-induced platelet activation (5µg/mL collagen I) -measured by ATP-release (A) -and platelet aggregation (B) are inhibited by CTRP-1 (5µg/mL). The inhibition of platelet aggregation by CTRP-1 is dose-dependent (C), for this experiment PRP was incubated with 1.25 µg/mL collagen I. 
